Overview Fundamentals API Earnings EOD API Sample Code Pricing

ALIGOS THERAPEUT. DL-01 (5WK F) stock market data APIs

€10.725 0(0%) as of October 17, 2024
Price chart is built with Anychart

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ALIGOS THERAPEUT. DL-01 Financial Data Overview

10.725
10.725
-
10.725
10.725
7.15-25.5
1 652 K
3 072 K
7 967 K
2.183
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '5WK',
Type: 'Common Stock',
Name: 'ALIGOS THERAPEUT. DL-01',
Exchange: 'F',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
CUSIP: NULL,
}

ALIGOS THERAPEUT. DL-01 Fundamental Data is available in our Financial Data APIs

  • Net Revenue 7 967 K
  • EBITDA -91 565 000
  • Earnings Per Share -13.15
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get ALIGOS THERAPEUT. DL-01 Earnings via APIs

  • Latest Release 2024-10-31
  • EPS/Forecast NaN

Get ALIGOS THERAPEUT. DL-01 End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com